VECTORMUNE® ND | BCH-LMO-SCBD-115064 | Living Modified Organism | Biosafety Clearing-House

Loading...
  |  

Living Modified Organism (LMO)

Decisions on the LMO Risk Assessments  
last updated: 25 Jul 2019
Living Modified Organism identity
The image below identifies the LMO through its unique identifier, trade name and a link to this page of the BCH. Click on it to download a larger image on your computer. For help on how to use it go to the LMO quick-links page.
VECTORMUNE® ND
EN
HVT-F/NDV
  • - Person: Dr Alexis Henry Gaetan Goux | BCH-CON-ID-114743-2
    Person
    Dr Alexis Henry Gaetan Goux
    President of CIBio,
    Rua Manuel Joaquim Filho, 303 Pulinia - SP Sao Paulo, Brazil 13140-000
    Sao Paulo,
    , Brazil
    Phone: +551938337700,
    Fax:
    Website:
    Related Organization
    Ceva Saude Animal Ltda (CEVA) ()
    Rua Manuel Joaquim Filho, 303 Pulinia - SP Sao Paulo, Brazil 13140-000
    Sao Paulo,
    , Brazil
    Phone: +551938337700,
    Fax:
    Website:
VECTORMUNE® ND is vaccine against Newcastle disease (ND) and Marek's Disease (MD). The vaccine contains modified Turkey Herpesvirus (Marek's disease vaccine; serotype 3), expressing fusion protein from Newcastle disease virus.
EN
The term “Recipient organism” refers to an organism (either already modified or non-modified) that was subjected to genetic modification, whereas “Parental organisms” refers to those that were involved in cross breeding or cell fusion.
Turkey Herpesvirus serotype 3
EN
  • VECTORMUNE® HVT-NDV + Rispens
    | Dr Alexis Henry Gaetan Goux Production of medical or pharmaceutical compounds (human or animal) - Vaccines
Characteristics of the modification process
p45/p46PecF
EN
  • Virus-mediated gene transfer
Some of these genetic elements may be present as fragments or truncated forms. Please see notes below, where applicable.
  • BCH-GENE-SCBD-105090-4 Fusion protein gene | (Newcastle disease virus)
    Protein coding sequence | Production of medical or pharmaceutical compounds (human or animal) (Vaccines)
  • BCH-GENE-SCBD-114749-2 CMV Early Enhancer | (HCMV, HHV-5)
    Enhancer
  • BCH-GENE-SCBD-105217-2 Beta-actin gene promoter | (Chicken, CHICK)
    Promoter
  • BCH-GENE-SCBD-114748-3 SV40 poly-adenylation signal | Macaca mulatta polyomavirus 1 (SV40, Simian vacuolating virus 40, simian virus 40, Rhesus macaque polyomavirus)
    Terminator
The recombinant virus contains an expression cassette located in the intergenic region between genes UL45 and UL46 Turkey Herpesvirus (HVT). The recombinant virus was created by transfecting chick embryo fibroblast cells with wild-type HVT strain FC126 and the plasmid vector p45/46PecF. During viral packaging, recombination of the genetic material occurred due to the homologous sequences of UL45 and UL46 flanking the expression cassette in the plasmid vector and recombinant viruses were produced.

During viral transcription, the Cytomegalovirus enhancer promotes strong transcription from the chicken (Gallus gallus) beta-actin promoter and transcribes the Newcastle disease virus fusion protein (Protein F) before terminating at the Macaca mulatta polyomavirus 1 poly-adenylation signal.

The recombinant virus is sufficient to create immunity to Newcastle disease virus and Merek's disease virus (Gallid alphaherpesvirus 2).
EN
LMO characteristics
EN
  • Vaccine
Detection method(s)
Protein Detection:
The expression of NDV Protein F was confirmed using Southern blotting.
EN
Additional Information
Records referencing this document Show in search
Record type Field Record(s)